biotech leader<\/a>, could have important catalysts this year. First, the company’s newer launches, Journavx for acute pain and Casgevy for sickle cell disease and beta thalassemia, should make meaningful progress. The company projects these products will generate at least $500 million in sales this year. That’s not that much. The drugmaker’s total revenue in 2025 was $12 billion.<\/p>\nHowever, Vertex has relied exclusively on its cystic fibrosis (CF) franchise to drive growth for a long time. Casgevy and Journavx are steadily ramping up their sales and could meaningfully contribute to top-line growth in the coming years. Second, Vertex Pharmaceuticals should make important clinical and regulatory progress in 2026. The company plans to request approval for zimislecel, an investigational medicine for Type 1 diabetes, this year.<\/p>\n
![\"Vertex](\"https:\/\/www.newsbeep.com\/il\/wp-content\/uploads\/2026\/02\/1772198109_393_.png\"\/)
<\/p>\n
Today’s Change<\/p>\n
(-0.60%) $-2.92<\/p>\n
Current Price<\/p>\n
$480.13<\/p>\n
Key Data Points<\/p>\n
Market Cap<\/p>\n
$122B<\/p>\n
Day’s Range<\/p>\n
$474.59 – $483.63<\/p>\n
52wk Range<\/p>\n
$362.50 – $519.68<\/p>\n
Volume<\/p>\n
124<\/p>\n
Avg Vol<\/p>\n
1.4M<\/p>\n
Gross Margin<\/p>\n
86.32%<\/p>\n
It should also release data from phase 3 studies for next-gen programs, including povetacicept for IgA Nephropathy and inaxaplin for APOL-1 mediated kidney disease. With these in its back pocket, Vertex Pharmaceuticals’ lineup will become even stronger and more diversified.<\/p>\n
The company can still ride its CF franchise for a while, but these newer products will ensure that, even if it encounters competition in its core area of expertise (it hasn’t had any meaningful competition yet), it can overcome it. Vertex’s strong lineup and innovative streak make the stock a buy this month.<\/p>\n","protected":false},"excerpt":{"rendered":"Patience should pay off with these two healthcare giants. Will the healthcare sector finally rebound in 2026, after…\n","protected":false},"author":2,"featured_media":313050,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[34],"tags":[163,521,85,46],"class_list":{"0":"post-313049","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-healthcare","8":"tag-health","9":"tag-healthcare","10":"tag-il","11":"tag-israel"},"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/posts\/313049","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/comments?post=313049"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/posts\/313049\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/media\/313050"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/media?parent=313049"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/categories?post=313049"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/tags?post=313049"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
![\"Person](\"https:\/\/www.newsbeep.com\/il\/wp-content\/uploads\/2026\/02\/1772198108_602_.jpeg\"\/)
<\/p>\n![\"CVS](\"https:\/\/www.newsbeep.com\/il\/wp-content\/uploads\/2026\/02\/1772198109_192_.png\"\/)
<\/p>\n